Metraipolis › archive › dc_7e4e7a937dd3

Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study — Europe PMC PMID:41080912

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41080912
DOI
10.1016/j.lanepe.2025.101471
License (as archived)
solo-consultazione
Archived
2026-11-09T17:28:50.862Z
SHA-256 of the archived text
436078329a293c20b8b6af676ac901ab5dcf4a79ddca114892177d99fdee1743
Stable URL of this page
https://metraipolis.com/documento/dc_7e4e7a937dd3

How to cite

Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study — Europe PMC PMID:41080912 — Europe PMC (en), https://europepmc.org/article/MED/41080912 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7e4e7a937dd3 (Metraipolis archive dc_7e4e7a937dd3, sha256 436078329a293c20b8b6af676ac901ab5dcf4a79ddca114892177d99fdee1743)
BibTeX
@misc{dc7e4e7a937dd3,
  title = {Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study — Europe PMC PMID:41080912},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41080912},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7e4e7a937dd3; sha256 436078329a293c20b8b6af676ac901ab5dcf4a79ddca114892177d99fdee1743},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41080912. Agents can read the archived copy with the MCP tool read_document.